Table 2.

Frequency and comparison of the IL28B and IFNL4 genotypes in resolving and chronically infected HCV patients

All subjects		Frequency of clearance (%)	Frequency of persistence (%)	Comparison	OR (95% CI)	p value
IL28B GT	CC	21 (63.6%)	10 (25.6%)			0.005*
	TT	02 (6.1%)	03 (7.7%)	CC vs CT + TT	0.197 (0.072–0.541)	0.001*
	CT	10 (30.3%)	26 (66.7%)	CT vs CC + TT	4.6 (1.697–12.469)	0.002
	CT + TT	12 (36.4%)	29 (74.4%)	TT vs CC + CT	1.292 (0.203–8.236)	0.786
INFL4 GT	ΔG/ΔG	01 (3.7%)	07 (17.9%)	ΔG/ΔG vs ΔG/TT + TT/TT	5.688 (0.657–49.231)	0.081
	ΔG/TT	10 (37%)	22 (56.4%)	ΔG/TT vs ΔG/ΔG + TT/TT	2.200 (0.850–6.012)	0.122
	TT/TT	16 (59.3%)	10 (25.6%)†*	TT/TT vs ΔG/ΔG + ΔG/TT	0.237 (0.083–0.679)	0.006*
Protective GT	CC-TT/TT	13 (54.17%)	09 (23.68%)			0.015*
Deleterious GT	nCC-nTT/TT	11 (45.83%)	29 (76.32%)

GT genotype. *Statistically significant. †*P = 0.014